Holen Sie sich die Stockscreener-App
2.01
1.26%
0.025
Handel nachbörslich:
2.03
0.02
+1.00%
Schlusskurs vom Vortag:
$1.985
Offen:
$2.01
24-Stunden-Volumen:
191.88K
Relative Volume:
1.76
Marktkapitalisierung:
$20.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.77M
KGV:
-0.6073
EPS:
-3.3097
Netto-Cashflow:
$-29.79M
1W Leistung:
-22.24%
1M Leistung:
-57.95%
6M Leistung:
-80.97%
1J Leistung:
-83.32%
1-Tages-Spanne:
$1.95
$2.025
1-Wochen-Bereich:
$1.95
$2.70
52-Wochen-Spanne:
$1.95
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
1448 NW MARKET STREET, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
2.01 | 20.05M | 0 | -34.77M | -29.79M | -3.3097 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Atossa Therapeutics Inc (ATOS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atossa Therapeutics Inc (ATOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atossa Therapeutics Inc (ATOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atossa Therapeutics Inc (ATOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atossa Therapeutics Inc (ATOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Atossa Therapeutics Inc (ATOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Atossa Therapeutics Inc (ATOS) Institutional Confidence - TradingKey
Atossa Therapeutics Inc (ATOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Atossa Therapeutics brings medical innovation to Hudson Institute strategic discussions - Traders Union
Atossa Therapeutics Inc (ATOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atossa Therapeutics (ATOS) Q1 2026 Earnings: Narrowing Losses with Positive EPS SurpriseRevenue Warning Signal - newsline.com
Atossa Therapeutics closes $4.5M registered direct offering By Investing.com - Investing.com Australia
Atossa Therapeutics closes $4.5M registered direct offering - Investing.com
Cancer-drug developer Atossa raises $4.5M, eyes $12M more - Stock Titan
Atossa Therapeutics Announces Up To $16.5 Million Registered Direct Offering - Pulse 2.0
Atossa Therapeutics examines biosecurity and scientific innovation after COVID 19 lessons - Traders Union
Atossa Therapeutics (NASDAQ: ATOS) sells 1.36M shares with warrants in $4.5M deal - Stock Titan
Atossa Therapeutics prices up to $16.5M direct offering - MSN
Market Movers | Winners: XXII, PPCB, CCHH | Losers: BCPC, ATOS, BATL - Trefis
Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance
Top Midday Decliners - Moomoo
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings - Benzinga
Dow Jumps Over 250 Points; US Initial Jobless Claims RiseAtossa Therapeutics (NASDAQ:ATOS), Big Tree C - Benzinga
Atossa Therapeutics Launches $16.5 Million Registered Direct Offering - marketscreener.com
Atossa Therapeutics stock tumbles on $4.5M stock offering - Investing.com UK
Atossa Therapeutics Announces Registered Direct Offering and Warrants - TipRanks
Atossa Therapeutics stock tumbles on $4.5M stock offering By Investing.com - Investing.com Nigeria
Atossa Therapeutics raises $4.5M in registered direct offering - Investing.com
Atossa Therapeutics raises $4.5M in registered direct offering By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Atossa Therapeutics Prices Registered Direct Offering at $3.30, Netting About $4.1 Million - TradingView
Atossa Therapeutics (ATOS) prices $3.30 registered direct stock and warrant sale - Stock Titan
Biotech Atossa targets up to $16.5M to fund clinical work - Stock Titan
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment - Proactive financial news
Atossa Therapeutics (ATOS) Climbs 1.79% as Shares Approach Key Resistance at $4.78Wedge Breakout - newsline.com
Lowering mammographic breast density could cut future cancer risk, ATOSSA THERAPEUTICS, INC. asserts - Traders Union
CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics - Yahoo Finance
Atossa Therapeutics (ATOS) Edges Higher on Modest Gains, Holds Above Key SupportReversal Trade - The Legal Advocate
ATOS News | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Cash from investing activities of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Atossa Therapeutics (ATOS) Highlights Promising Data for (Z)-End - GuruFocus
Atossa presents preclinical data on breast cancer drug at ASCO - Investing.com UK
Atossa Presents New Data Highlighting (Z)-Endoxifen's Potential in Breast Cancer - Intellectia AI
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PR Newswire
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics (ATOS) Holds Steady Near Support Amid Modest DeclineScalping Stock Signals - newsline.com
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy - BioSpace
Atossa Therapeutics advances research on Z-endoxifen for Duchenne muscular dystrophy - Traders Union
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):